Loading stock data…
NOVARTIS N (NOVN.SW)
CHF 126.20-0.08 (-0.06%)
Market OpenUpdated 11:31 AM EDT
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Novartis AG in the Healthcare sector is trading at $126.20 with a market capitalization of $232.3B. Wall Street consensus targets $124.74 (21 analysts), implying a -1.2% move over the next 12 months. The stock is currently near its 52-week high of $131.00, remaining 13.8% above its 200-day moving average. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Total Revenue | $13.62B↓ | $14.84B↑ | $14.36B↑ | $13.86B↑ | $13.52B |
| Gross Profit | $10.39B↓ | $11.51B↑ | $10.82B↑ | $10.25B↑ | $10.06B |
| Operating Income | $4.66B↓ | $4.86B↑ | $4.50B↑ | $3.62B↓ | $4.24B |
| Net Income | $3.61B↓ | $4.04B↑ | $3.93B↑ | $2.41B↓ | $3.16B |
Peer Comparison
JNJUNHPFE
Fundamentals
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart f...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$232.33B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
21.90
Beta
Defensive asset. Lower volatility than the S&P 500.
0.49
Div Yield
Strong income play. Yield provides a meaningful total return floor.
311.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
34.93%
Volume
Today's trading volume
2.37M
Recent News
INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura
Incyte shares hit a 52-week high as Opzelura gains regulatory momentum, pipeline advances and a CMS settlement boosts investor sentiment.
Johnson & Johnson (JNJ) Surges 4.0%: Is This an Indication of Further Gains?
Johnson & Johnson (JNJ) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Novartis (SWX:NOVN) Forms Antares Cancer Partnership And Expands Disability Access Efforts
Novartis (SWX:NOVN) announced a new oncology R&D partnership with Antares Therapeutics to pursue small molecule drugs for historically undruggable cancer targets. The company is also expanding patient impact initiatives through a collaboration with Becoming rentABLE to improve accessible travel options for people living with spinal muscular atrophy. These developments broaden Novartis’ focus across cancer drug discovery and real world quality of life support for patients. For investors...
Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump?
Biogen is betting on Leqembi, Skyclarys and Zurzuvae to offset declining legacy drug sales, but replacing lost revenues may take time.
The Zacks Analyst Blog Highlights Micron, MUU, MULL, SHOC,CHPX and FTXL
Micron soared after crushing Q3 estimates, forecasting stronger Q4 sales and highlighting AI-driven memory demand. See ETFs with significant MU exposure.